Rigrodsky & Long, P.A. Investigates Buyout of Clinical Data, Inc. - CLDA

WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Clinical Data, Inc. (“Clinical Data” or the “Company”) (Nasdaq: CLDA) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Forest Laboratories, Inc. (“Forest Labs”) (NYSE: FRX) in a transaction with a total value of approximately $1.2 billion on a fully diluted basis, net of net cash acquired. Click here to learn how to join the action: http://www.rigrodskylong.com/news/ClinicalDataInc-CLDA.